Axcelead DDP was rated as “Excellent” by Japan Agency for Medical Research and Development (AMED) in a program for “Drug Discovery Seeds Development”, which demonstrates Axcelead DDP’s ability of integrated and high-quality drug discovery research.
We are excited to inform that our group company, Axcelead Drug Discovery Partners Inc. (Axcelead DDP) was rated as “Excellent” among the 7 organizations, by Japan Agency for Medical Research and Development (AMED)’s “Project Support for Drug Discovery – Infrastructure Program for Drug Discovery Seeds Development” which Axcelead DDP was elected in 2017.
This project, led by Axcelead DDP, aims to promote academia’s seeds and concepts into attractive projects for pharmaceutical companies, and by adding high value to projects at all stages of drug discovery, it can achieve to form the drug discovery ecosystem and create innovative drugs. In this project, Axcelead DDP has supported 24 research projects.
The Axcelead Group will continue to promote high quality services aimed at the efficient commercialization of outstanding drug discovery seeds from academia.
For more information, please visit Axcelead DDP’s corporate page(https://www.axcelead.com/en/news-release/5775/)
